CDT Equity Inc
Company Profile
Business description
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
Contact
4581 Tamiami Trail North
Suite 200
NaplesFL34103
USAT: +1 646 491-9132
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
ASX energy giant undervalued despite commissioning challenges
stocks
Undervalued ASX share upgrades guidance
stocks
ASX major bank drives strong quarterly profit
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,098.00 | 65.70 | 0.73% |
| CAC 40 | 8,406.06 | 33.78 | 0.40% |
| DAX 40 | 25,361.03 | 262.03 | 1.04% |
| Dow JONES (US) | 52,210.08 | 262.83 | 0.51% |
| FTSE 100 | 10,781.75 | 45.52 | 0.42% |
| HKSE | 25,178.21 | 28.97 | -0.11% |
| NASDAQ | 24,932.08 | 43.74 | -0.18% |
| Nikkei 225 | 62,178.87 | 2,752.32 | -4.24% |
| NZX 50 Index | 13,875.91 | 25.22 | 0.18% |
| S&P 500 | 7,413.18 | 1.20 | 0.02% |
| S&P/ASX 200 | 8,934.70 | 72.50 | 0.82% |
| SSE Composite Index | 3,820.52 | 37.72 | -0.98% |